U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H13N5O4
Molecular Weight 255.2306
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GANCICLOVIR

SMILES

NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1

InChI

InChIKey=IRSCQMHQWWYFCW-UHFFFAOYSA-N
InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)

HIDE SMILES / InChI

Molecular Formula C9H13N5O4
Molecular Weight 255.2306
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

There is no information in the literature about pharmacological and biological application of definite isomer: R of valganciclovir. However, is known, that valganciclovir, existing, as a mixture of R and S diasteriomers, is the active ingredient in Valcyte, which is used as an antiviral medication given to patients who have a high chance of developing cytomegalovirus (CMV) disease after receiving a heart, kidney, or kidney-pancreas transplant. It was proposed, that stable aqueous solutions of valganciclovir can be prepared in aqueous solutions at acidic pHs but these solutions will exist as a mixture of isomers: R and S

CNS Activity

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector.
2001 Apr
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
2001 Apr 1
Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene.
2001 Apr 15
A time to live, a time to die.
2001 Apr 15
Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity.
2001 Feb
[Cytomegalovirus rhombencephalomyelitis in an immunocompetent subject].
2001 Feb
Toxic megacolon: remember cytomegalovirus.
2001 Mar
Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient.
2001 Mar
Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis.
2001 Mar
Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model.
2001 Mar 1
Patents

Sample Use Guides

In Vivo Use Guide
5 mg/kg every 12 hours (given intravenously at a constant rate over 1 hour) (induction treatment) and 5 mg/kg given as a constant-rate intravenous infusion over 1 hour once daily, 7 days per week, or 6 mg/kg once daily, 5 days per week (maintenance treatment).
Route of Administration: Intravenous
In Vitro Use Guide
IC50 is from 0.02 to 3.48 ug/mL
Substance Class Chemical
Created
by admin
on Tue Mar 06 12:08:08 UTC 2018
Edited
by admin
on Tue Mar 06 12:08:08 UTC 2018
Record UNII
P9G3CKZ4P5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GANCICLOVIR
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
BW 759U
Code English
GANCICLOVIR [HSDB]
Common Name English
VITRASERT IMPLANT
Brand Name English
GANCICLOVIR [EP]
Common Name English
GANCICLOVIR [WHO-DD]
Common Name English
GANCICLOVIR [EMA EPAR]
Common Name English
9-((2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY)METHYL)GUANINE
Systematic Name English
GANCICLOVIR [USP]
Common Name English
GANCICLOVIR [USAN]
Common Name English
6H-PURIN-6-ONE, 2-AMINO-1,9-DIHYDRO-9-((2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY)METHYL)-
Systematic Name English
GANCICLOVIR [MART.]
Common Name English
VITRASERT
Brand Name English
ZIRGAN
Brand Name English
GANCICLOVIR [ORANGE BOOK]
Common Name English
RS-21592
Code English
BW-759U
Code English
GANCICLOVIR [INN]
Common Name English
GANCICLOVIR [VANDF]
Common Name English
GANCICLOVIR [MI]
Common Name English
GANCICLOVIR [USP-RS]
Common Name English
GANCICLOVIR [JAN]
Common Name English
GANCYCLOVIR
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS VITRASERT IMPLANT (WITHDRAWN: HIV INFECTIONS)
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
NDF-RT N0000020060
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
LIVERTOX 449
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
NDF-RT N0000175461
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
EMA ASSESSMENT REPORTS VITRASERT IMPLANT (WITHDRAWN: CYTOMEGALOVIRUS RETINITIS)
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
NDF-RT N0000175466
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
WHO-VATC QS01AD09
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
NDF-RT N0000175459
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
WHO-ATC J05AB06
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
WHO-VATC QJ05AB06
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
NDF-RT N0000175459
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
WHO-ATC S01AD09
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
NDF-RT N0000175459
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
Code System Code Type Description
EVMPD
SUB07881MIG
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY
EPA CompTox
82410-32-0
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY
DRUG BANK
DB01004
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY
NCI_THESAURUS
C517
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY
PUBCHEM
3454
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY SWITZERF
ChEMBL
CHEMBL182
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY
RXCUI
4678
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY RxNorm
INN
6023
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY
MERCK INDEX
M5663
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY Merck Index
HSDB
82410-32-0
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY
CAS
82410-32-0
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY
MESH
D015774
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY
WIKIPEDIA
GANCICLOVIR
Created by admin on Tue Mar 06 12:08:08 UTC 2018 , Edited by admin on Tue Mar 06 12:08:08 UTC 2018
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
Vmax
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
Km
TRANSPORTER -> SUBSTRATE
Vmax
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TRANSPORTER -> SUBSTRATE
Km
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY